
Molecular Partners Investor Relations Material
Latest events

H2 2024
Molecular Partners
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Molecular Partners AG
Access all reports
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, canton of Zürich, Switzerland. Founded in 2004 by researchers from the University of Zürich, the company specializes in the development of a novel class of custom-built protein therapeutics known as Designed Ankyrin Repeat Proteins (DARPins). These DARPins are versatile and potent small-protein therapies with applications across various disease areas, including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners has established itself in the biotechnology industry by leveraging its DARPin platform to create therapies that aim to surpass the limitations of current treatment options. Molecular Partners AG's shares are listed on the SIX Swiss Exchange and the Nasdaq.
Key slides for Molecular Partners AG


H2 2024
Molecular Partners AG


H2 2024
Molecular Partners AG
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
MOLN
Country
🇺🇸 United States